Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project.
about
The role of epigenetics in kidney malignanciesCrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanismsTransmembrane 6 superfamily 1 (Tm6sf1) is a novel lysosomal transmembrane proteinCombined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.An emerging understanding of long noncoding RNAs in kidney cancer.UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses.Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved.The epigenetic landscape of renal cancer.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma.MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data.The epigenetic landscape of clear-cell renal cell carcinoma.The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
P2860
Q26801233-CCFFCBBC-08BC-4041-827F-6E0C656FC269Q28392625-0EABB298-3B89-4D3D-93B1-C0C8B66E9E76Q28593295-C78A49A0-25C4-4EA6-AA88-1E5E30D85F1FQ35930811-7791738E-F8A8-4ACC-A60C-E2E4A99323D5Q38210909-86453133-C3CF-4D28-A3C1-EFBED97D0E47Q38667837-3B53F686-8CF9-4D00-9016-492E2E25661EQ38679148-81767F32-DF25-420E-B968-AE28E8A11E4DQ38854862-08596499-9616-41F6-920C-18DDBAFF1FD7Q39021700-9AF03B3E-2406-42E7-946D-0D687854C29BQ40028818-7B41B6A4-2D60-4605-8524-E184A07EE6AAQ40937833-19DEE5E4-87C8-4FF0-BD09-36ECF1977BD8Q47162128-07B467C6-CE7C-4195-AE70-C17F0D45E764Q47271339-6E091846-5D63-42A8-A39A-58E8967CD6B0Q51091490-8C9ECB74-0CD2-4F66-AF97-EB469EEE92E8Q52607313-ACB1B549-4F22-43E5-BB4E-2E5A99E0FD8E
P2860
Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@en
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@nl
type
label
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@en
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@nl
prefLabel
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@en
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@nl
P2093
P2860
P1433
P1476
Tumor-specific hypermethylatio ...... Cell Carcinoma (KIRC) project.
@en
P2093
Christopher J Ricketts
Victoria K Hill
W Marston Linehan
P2860
P304
P356
10.1371/JOURNAL.PONE.0085621
P407
P577
2014-01-15T00:00:00Z